OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

Core Insights - OSE Immunotherapeutics has announced a strategic amendment to its partnership with AbbVie regarding the development of ABBV-230, a monoclonal antibody aimed at addressing chronic and severe inflammation [1][2] - The amendment allows OSE Immunotherapeutics to regain control over the early-stage development of ABBV-230, while AbbVie retains rights for future development and commercialization after Phase 1 [2][5] Summary by Sections Partnership Agreement - The revised agreement reflects both companies' enthusiasm for ABBV-230 and aligns development responsibilities with their respective strengths [2] - OSE Immunotherapeutics will lead the preclinical and Phase 1 development of ABBV-230, leveraging its immunology expertise [7] Financial Terms - All existing commercialization rights, including royalties on global net sales and sales-based milestone payments, remain unchanged [7] - OSE Immunotherapeutics will not receive the previously anticipated milestone payment tied to the initiation of Phase 1 but will be eligible for milestone payments in subsequent development stages if AbbVie advances the candidate [7] Product Development - ChemR23, the dual-function receptor involved in inflammation, is central to the development of ABBV-230, which aims to be a first-in-class therapy for inflammation resolution [4]